전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,019 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 20Status Recruiting
CGTLimited DatastaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 19Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Favezelimab (Favezelimab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 18Status Discontinued
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Favezelimab/Pembrolizumab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 18Status Active
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
AntibodyLimited DatastaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 16Status Active
CGTLimited DatastaleBeam Therapeutics Inc.Phase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Recruiting
AntibodyLimited DatastaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 16Status Recruiting
CGTLimited DatastalePaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 15Status Recruiting
CGTLimited DatastaleLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 15Status Recruiting
AntibodyLimited DatastaleRochePhase 1

trastuzumab (Herceptin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab)

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#Antibody#Phase1#monoclonal-antibody#AdvancedMalignantSolidNeoplasm+1
Trials 15Status Discontinued
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
CGTLimited DatastaleTaizhou HoudeAoke Biomedical Co…Phase 1

OH2 oncolytic virus (OH2 oncolytic virus)

Digestive System Neoplasms · Digestive System Neoplasms

#DigestiveSystemNeoplasms#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Adult T-Cell Lymphoma/Leukaemia; Anaplastic Large Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 13Status Active
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 13Status Recruiting
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 13Status Recruiting
CGTAAVLimited DatastaleByron LamPhase 2

10e11 vg (Injection of AAV2-REP1, Injection of AAV2-REP1 (10e11 vg))

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 13Status Active

10 / 51 pages

← PreviousNext →